This article is a correction to:
Antithyroglobulin Antibody Variation During Follow-Up Has a Good Prognostic Value for Preoperative Antithyroglobulin Antibody-Positive Differentiated Thyroid Cancer Patients: A Retrospective Study in Southwest China
Qianhui Liu
Guixing LiBy Liu Q, Yin M and Li G (2021). Front. Endocrinol. 12:774275. doi: 10.3389/fendo.2021.774275
In the original article, there was a mistake in Table 6 as published. We recently found by ourselves that the p values of T2 and “6 months after 131I therapy ≥ − 77.9%” were incorrect owing to the careless recording. Furthermore, the corresponding text of Table 6 should be corrected as “In multivariate analysis, variations in the TgAb at 1 year after 131I therapy ≥ − 77.4% and 2 years after 131I therapy ≥-88.6% were independent predictive factors for a tumour-free status at the end of follow-up.” The corrected Table 6 appears below.
TABLE 6
Table 6 Multivariate analysis of predictors of a tumour-free clinical outcome.
In the original article, there was an expression error. A correction has been made to the Results section ”Change Trends of Antithyroglobulin Antibody and Comparisons of the Levels of Antithyroglobulin Antibody at Different Time Points”: “In all groups except Group C, small increases were observed in the levels of TgAb at 1 month after 131I therapy (d) compared with those before 131I therapy (c)”.
Moreover, in the original article, there were two errors in Discussion. A correction has been made to Discussion, paragraph 2, the last sentence: “Additionally, we observed a slight rise in TgAb at 1 month after 131I therapy in most groups”, and Discussion, paragraph 3: “and we found that the variations of TgAb > −77.4% at 1 year after 131I therapy, and TgAb > −88.6% at 2 years after 131I therapy were independent predictive factors for a tumour-free status at the end of follow-up.”
The authors apologize for these errors and state that these do not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: thyroid cancer, prognosis, antithyroglobulin, biomarker, DTC (differentiated thyroid cancer)
Citation: Liu Q, Yin M and Li G (2022) Corrigendum: Antithyroglobulin Antibody Variation During Follow-Up Has a Good Prognostic Value for Preoperative Antithyroglobulin Antibody-Positive Differentiated Thyroid Cancer Patients: A Retrospective Study in Southwest China. Front. Endocrinol. 13:899184. doi: 10.3389/fendo.2022.899184
Received: 18 March 2022; Accepted: 29 March 2022;
Published: 27 April 2022.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2022 Liu, Yin and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Guixing Li, liguixing27@163.com